Navigation Links
Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February
Date:1/20/2012

SEATTLE, Jan. 20, 2012  /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, following discussions with the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"), the CHMP may issue an opinion on CTI's Marketing Authorization Application ("MAA") for Pixuvri in mid-February. In the interim, CTI will continue to work with the CHMP on the Summary of Product Characteristics and other labeling items for Pixuvri. CTI is seeking an authorization to market Pixuvri in the E.U. for the treatment of adult patients with multiple relapsed or refractory aggressive non-Hodgkin's B cell lymphomas ("NHL"). If approved by the EMA, Pixuvri would address an unmet medical need, as there are no approved therapies for these patients.

In the U.S., the Food and Drug Administration ("FDA") has set a Prescription Drug User Fee Act ("PDUFA") goal date of April 24, 2012 for a decision on the New Drug Application for Pixuvri in the same indication.

About Pixuvri (pixantrone)

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
2. European mountain vegetation shows effects of warmer climate
3. DTU is participating in a European network on measurement of greenhouse gases
4. Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux
5. UK invests £75 million in European research infrastructure to support knowledge-based economy
6. EMBO awards Installation Grants to 7 European scientists
7. How does a plant survive with few mates or pollinators? A European herb has figured out its own way
8. New European project launched to address shortcomings in climate data
9. Misleading morphology: 3 European parasitoid wasp species are seasonal forms of just 1
10. Genomatix to partner in $41 million European epigenomics consortium
11. Pesticides pollute European waterbodies more than previously thought
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... November 2014)—In support of a bold quest to rid ... Gates Foundation today announced an award of US$156 million ... (MVI) in building new vaccines that will interrupt the ... "accelerating to zero" agenda. Such vaccines would ensure that ... called an "immunological bed net." , This approach ...
(Date:11/2/2014)... walk into a bar and bump into a biologist . ... to some late-night nerd sketch, researchers have taken this premise ... biology, namely, finding meaning in the rising oceans of genomic ... cancer mutations that genome-wide studies are publishing at a dizzying ... parse the signal from the noise (and there is no ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... of some insects or the deep black of a ... the nanostructure of a fly,s eyes, according to Penn ... and inexpensively copy biological surface structures. "Only a ... says Akhlesh Lakhtakia, the Charles Godfrey Binder (Endowed) Professor ...
... size guidelines for all-terrain vehicles (ATV) are inadequate to ... results from a study by researchers at the University ... found that national ATV size guidelines for youth ... frame or engine size do not assure a ...
... of sedentary and overweight older people placed on a four-month ... more fat, compared to older sedentary people who were placed ... study also showed that when older people diet without exercising, ... said senior researcher Bret H. Goodpaster. When they combined weight ...
Cached Biology News:Coating copies microscopic biological surfaces 2Coating copies microscopic biological surfaces 3Study finds ATV guidelines inadequate 2Older people who diet without exercising lose valuable muscle mass 2
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood Registry® ... of the 10th Annual World Stem Cell Summit, the largest ... The 2014 World Stem Cell Summit will be held December ... Texas . The World Stem ... of lifesaving cures and therapies, convening the most prominent figures ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... Empowers Users to Take Full Control of the ... to Results Disclosure - while Adhering to Changing ... to Manage Their Clinical Trial Registration and Results ... ( http://www.intrasphere.com ), a ...
... , - European Operating ... Healthcare Educational Program, Accepted,for Accreditation , ... healthcare barrier,protective solutions, has announced it has taken a ... the area of continued,education. , ...
... developed an entirely new method for starting chemical reactions. ... control catalytic activity one of the most fundamental ... reactions with mechanical force. This discovery paves the way ... influence of mechanical tension. The results of their research ...
Cached Biology Technology:Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4A molecular ripcord for chemical reactions 2
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
... Silver Staining Kit is uniquely formulated ... with minimal protein modification for optimal ... problems associated with traditional silver stains ... because the reagents used do not ...
...
Biology Products: